Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 4/20 | 0.62 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.59 |
| ▸ | MDM4 | O15151 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | TNF | P01375 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29382791 | 1.00 | TLR2 (0.62) | TLR2MDM2MDM4TP53CASP3 | |
| SCHEMBL1000115 | 1.00 | TLR2 (0.62) | TLR2MDM2MDM4TP53CASP3 | |
| SCHEMBL30645689 | 1.00 | TLR2 (0.62) | TLR2MDM2MDM4TP53CASP3 | |
| SCHEMBL1044856 | 1.00 | TLR2 (0.62) | TLR2MDM2MDM4TP53CASP3 | |
| SCHEMBL29503829 | 1.00 | TLR2 (0.62) | TLR2MDM2MDM4TP53CASP3 | |
| SCHEMBL7420121 | 1.00 | TLR2 (0.62) | TLR2MDM2MDM4TP53CASP3 | |
| SCHEMBL29367120 | 1.00 | TLR2 (0.62) | TLR2MDM2MDM4TP53CASP3 | |
| SCHEMBL14996025 | 0.96 | TLR2 (0.64) | TLR2MDM2MDM4TP53CASP3 | |
| SCHEMBL14497949 | 0.96 | TLR2 (0.64) | TLR2MDM2MDM4TP53CASP3 | |
| SCHEMBL30802520 | 0.96 | TLR2 (0.64) | TLR2MDM2MDM4TP53CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250090699-A1 | FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2025-03-20 | — | — | US | disclosed |
| US-20240409585-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-12-12 | — | — | US | disclosed |
| US-12097237-B2 | Small molecule Ras inhibitors | OHIO STATE INNOVATION FOUNDATION (US) | 2024-09-24 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| EP-4373835-A1 | MACROCYLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2024-05-29 | — | — | EP | disclosed |
| US-20240158438-A1 | POLYPEPTIDE COMPOUND AND APPLICATION THEREOF | CHENGDU SINTANOVO BIOTECHNOLOGY CO., LTD. (CN) | 2024-05-16 | — | — | US | disclosed |
| CN-117940445-A | Macrocyclic immunomodulators | 百时美施贵宝公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-114805487-B | Polypeptide compound and application thereof | 成都诺和晟泰生物科技有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-20240066132-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | NOVARTIS AG (CH) | 2024-02-29 | — | — | US | disclosed |
| EP-4321525-A1 | POLYPEPTIDE COMPOUND AND APPLICATION THEREOF | Chengdu Sintanovo Biotechnology Co., Ltd (CN) | 2024-02-14 | — | — | EP | disclosed |
| US-11752211-B2 | Fatty acids and their use in conjugation to biomolecules | NOVARTIS AG (CH) | 2023-09-12 | — | — | US | disclosed |
| CN-113072617-B | Polypeptide compound and application thereof | 成都诺和晟泰生物科技有限公司 | 2023-08-08 | — | — | CN | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| WO-2023004240-A1 | MACROCYLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-26 | — | — | WO | disclosed |
| WO-2022206587-A1 | POLYPEPTIDE COMPOUND AND APPLICATION THEREOF | 成都诺和晟泰生物科技有限公司 | 2022-10-06 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| CN-114805487-A | Polypeptide compound and application thereof | 成都诺和晟泰生物科技有限公司 | 2022-07-29 | — | — | CN | disclosed |
| EP-3988170-A1 | FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | Novartis AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| CN-114133443-A | Fatty acids and their use in conjugation with biomolecules | 诺华股份有限公司 | 2022-03-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12097237-B2 | Small molecule Ras inhibitors | KRAS, HRAS, NRAS | TLR2 4770/4885MDM2 195/4885MDM4 904/4885 |
| US-20240066132-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | FABP1, FABP2, FABP3 | TLR2 415/4885MDM2 2413/4885MDM4 4731/4885 |
| US-11752211-B2 | Fatty acids and their use in conjugation to biomolecules | FABP1, FABP2, FABP3 | TLR2 373/4885MDM2 2188/4885MDM4 4725/4885 |
| US-20240158438-A1 | POLYPEPTIDE COMPOUND AND APPLICATION THEREOF | GHSR, GHRHR, GIPR | TLR2 416/4885MDM2 4290/4885MDM4 4883/4885 |
| US-20250090699-A1 | FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | FAP, FIBP, FGF23 | TLR2 3566/4885MDM2 1455/4885MDM4 2377/4885 |
| US-20240409585-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | TLR2 123/4885MDM2 765/4885MDM4 1149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.